サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1701659

PARP阻害薬バイオマーカーの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

PARP Inhibitor Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
PARP阻害薬バイオマーカーの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月07日
発行: Persistence Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • PARP阻害薬バイオマーカーの市場規模：10億3,530万米ドル（2025年）
  • 予測される市場金額：18億3,340万米ドル（2032年）
  • 世界市場の成長率：8.5%（2025年～2032年のCAGR）

PARP阻害薬バイオマーカー市場 - レポート範囲

PARP（ポリADPリボースポリメラーゼ）阻害薬バイオマーカーは、PARP阻害薬治療の恩恵を受ける見込みがある患者を特定する上で極めて重要であり、特に腫瘍用途において重要です。これらのバイオマーカーには、BRCA1/2変異、相同組換え修復欠損（HRD）、その他のDNA損傷応答（DDR）経路の変化が含まれます。市場は、特に卵巣がん、乳がん、前立腺がん、膵臓がんなどの治療において臨床医を支援することで、プレシジョンオンコロジーの実践に寄与しています。個別化医療の需要が高まるにつれて、バイオマーカー主導の治療アプローチの採用が加速しています。ゲノムプロファイリング、次世代シーケンシング（NGS）、コンパニオン診断の進歩が市場成長に大きく寄与しています。

市場成長の促進要因

世界のPARP阻害薬バイオマーカー市場は、がん罹患率の上昇と標的治療に対する需要の高まりによって牽引されています。PARP阻害薬が複数のがんの治療薬として承認されるにつれ、バイオマーカーの状態に基づいて適格な患者を特定するコンパニオン診断検査のニーズが高まっています。PARP阻害薬に対する反応性の予測因子としてBRCA遺伝子変異やHRDに対する認識が高まっていることが、バイオマーカー検査数を押し上げています。さらに、維持療法や併用療法におけるPARP阻害薬の利用の拡大が、バイオマーカー研究への投資を促進しています。プレシジョンオンコロジーを推進する政府の取り組みや、ゲノム医療インフラへの投資の拡大も市場成長を後押ししています。

市場抑制要因

PARP阻害薬バイオマーカー市場は、大きな成長可能性にもかかわらず、複数の制限に直面しています。バイオマーカー検査や次世代シーケンシング技術に関連する高いコストが、特に中低所得地域における課題となっています。コンパニオン診断薬を取り巻く償還のハードルや規制の複雑性は、新しい検査の市場参入を遅らせる可能性があります。加えて、PARP阻害薬の適格性を調べるバイオマーカー検査に関する臨床医や患者の認識が限定的であることが、より広範な採用を妨げています。検査基準のばらつきや専門的な検査施設へのアクセスが、未開発地域における市場拡大をさらに抑制しています。

市場機会

PARP阻害薬の適用範囲を拡大できるBRCA遺伝子変異以外の新規バイオマーカーの開発には大きな機会が存在します。コンパニオン診断を共同開発する製薬企業と診断薬企業の提携は有望な成長手段となります。ゲノムデータの解釈におけるAIと機械学習の統合は、バイオマーカー探索と臨床意思決定を強化すると予測されます。さらに、遠隔医療や在宅遺伝子検査プラットフォームの普及が進むことで、バイオマーカー検査や患者へのアウトリーチに新たなチャネルが提供されます。新興市場への進出とリキッドバイオプシー技術の進化も、未開発の成長可能性を示しています。

当レポートでは、世界のPARP阻害薬バイオマーカー市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 製品採用分析
  • 規制情勢
  • ポーターのファイブフォース分析
  • PESTLE分析
  • プロモーション戦略：主要企業別

第4章 世界のPARP阻害薬バイオマーカー市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界のPARP阻害薬バイオマーカー市場の見通し：製品
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：製品別（2019年～2024年）
    • 現在の市場規模の分析と予測：製品別（2025年～2032年）
    • 市場の魅力分析：製品
  • 世界のPARP阻害薬バイオマーカー市場の見通し：用途
    • イントロダクション/主な調査結果
    • 市場規模の実績：用途別（2019年～2024年）
    • 現在の市場規模の分析と予測：用途別（2025年～2032年）
    • 市場の魅力分析：用途
  • 世界のPARP阻害薬バイオマーカー市場の見通し：エンドユーザー
    • イントロダクション/主な調査結果
    • 市場規模の実績：エンドユーザー別（2019年～2024年）
    • 現在の市場規模の分析と予測：エンドユーザー別（2025年～2032年）
    • 市場の魅力分析：エンドユーザー

第5章 世界のPARP阻害薬バイオマーカー市場の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米のPARP阻害薬バイオマーカー市場の見通し

第7章 欧州のPARP阻害薬バイオマーカー市場の見通し

第8章 東アジアのPARP阻害薬バイオマーカー市場の見通し

第9章 南アジア・オセアニアのPARP阻害薬バイオマーカー市場の見通し

第10章 ラテンアメリカのPARP阻害薬バイオマーカー市場の見通し

第11章 中東・アフリカのPARP阻害薬バイオマーカー市場の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • Myriad Genetics, Inc.
    • Illumina, Inc.
    • Amoy Diagnostics Co., Ltd.
    • QIAGEN
    • Agilent Technologies, Inc.
    • Quest Diagnostics Incorporated
    • Foundation Medicine, Inc.
    • OncoDNA
    • 4baseCare
    • AstraZeneca
    • Laboratory Corporation of America (R) Holdings
    • Genekor | MEDICAL S.A
    • Cambridge Bioscience Limited
    • BPS Bioscience, Inc.
    • BMG Labtech
    • R&D Systems, Inc (BioTechne)
    • BellBrook Labs
    • Abyntek Biopharma S.L.
    • Epic Sciences
    • Reaction Biology

第13章 付録

目次
Product Code: PMRREP35185

Persistence Market Research has recently released a comprehensive report on the worldwide market for PARP inhibitor biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global PARP inhibitor biomarkers market from 2025 to 2032.

Key Insights:

  • PARP Inhibitor Biomarkers Market Size (2025E): USD 1,035.3 Million
  • Projected Market Value (2032F): USD 1,833.4 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

PARP Inhibitor Biomarkers Market - Report Scope:

PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.

Market Growth Drivers:

The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.

Market Restraints:

Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.

Market Opportunities:

Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the PARP inhibitor biomarkers market globally?
  • Which biomarker types and cancer indications are driving the adoption of PARP inhibitor testing?
  • How are technological innovations influencing the competitive landscape of the PARP inhibitor biomarkers market?
  • Who are the key players contributing to the market, and what strategies are they using to strengthen their positions?
  • What are the emerging trends and future prospects in the global PARP inhibitor biomarkers market?

Competitive Intelligence and Business Strategy:

Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.

Key Companies Profiled:

  • Myriad Genetics, Inc.
  • Illumina, Inc.
  • Amoy Diagnostics Co., Ltd.
  • QIAGEN
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Foundation Medicine, Inc.
  • OncoDNA
  • 4baseCare
  • AstraZeneca
  • Laboratory Corporation of America(R) Holdings
  • Genekor | MEDICAL S.A
  • Cambridge Bioscience Limited
  • BPS Bioscience, Inc.
  • BMG Labtech
  • R&D Systems, Inc (BioTechne)
  • BellBrook Labs
  • Abyntek Biopharma S.L.
  • Epic Sciences
  • Reaction Biology

PARP Inhibitor Biomarkers Market Segmentation

By Product:

  • BRCA 1 & 2 Testing Kits
  • Homologous Recombination Deficiency (HRD) Testing Kits
  • Homologous Recombination Repair (HRR) Testing Kits
  • Others

By Application:

  • Ovarian Cancer
  • Breast Cancer
  • Others

By End User:

  • Hospitals
  • Pharmaceutical Companies
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global PARP Inhibitor Biomarkers Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global PARP Inhibitor Biomarkers Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global PARP Inhibitor Biomarkers Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. BRCA 1 & 2 Testing Kits
      • 4.3.3.2. Homologous Recombination Deficiency (HRD) Testing Kits
      • 4.3.3.3. Homologous Recombination Repair (HRR) Testing Kits
      • 4.3.3.4. Others
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global PARP Inhibitor Biomarkers Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Ovarian Cancer
      • 4.4.3.2. Breast Cancer
      • 4.4.3.3. Others
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global PARP Inhibitor Biomarkers Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Pharmaceutical Companies
      • 4.5.3.3. Diagnostic Laboratories
      • 4.5.3.4. Academic and Research Institutions
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global PARP Inhibitor Biomarkers Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America PARP Inhibitor Biomarkers Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. BRCA 1 & 2 Testing Kits
    • 6.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 6.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 6.4.4. Others
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Ovarian Cancer
    • 6.5.2. Breast Cancer
    • 6.5.3. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Pharmaceutical Companies
    • 6.6.3. Diagnostic Laboratories
    • 6.6.4. Academic and Research Institutions
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe PARP Inhibitor Biomarkers Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. BRCA 1 & 2 Testing Kits
    • 7.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 7.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 7.4.4. Others
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Ovarian Cancer
    • 7.5.2. Breast Cancer
    • 7.5.3. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Pharmaceutical Companies
    • 7.6.3. Diagnostic Laboratories
    • 7.6.4. Academic and Research Institutions
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia PARP Inhibitor Biomarkers Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. BRCA 1 & 2 Testing Kits
    • 8.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 8.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 8.4.4. Others
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Ovarian Cancer
    • 8.5.2. Breast Cancer
    • 8.5.3. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Pharmaceutical Companies
    • 8.6.3. Diagnostic Laboratories
    • 8.6.4. Academic and Research Institutions
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania PARP Inhibitor Biomarkers Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. BRCA 1 & 2 Testing Kits
    • 9.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 9.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 9.4.4. Others
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Ovarian Cancer
    • 9.5.2. Breast Cancer
    • 9.5.3. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Pharmaceutical Companies
    • 9.6.3. Diagnostic Laboratories
    • 9.6.4. Academic and Research Institutions
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America PARP Inhibitor Biomarkers Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. BRCA 1 & 2 Testing Kits
    • 10.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 10.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 10.4.4. Others
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Ovarian Cancer
    • 10.5.2. Breast Cancer
    • 10.5.3. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Pharmaceutical Companies
    • 10.6.3. Diagnostic Laboratories
    • 10.6.4. Academic and Research Institutions
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. BRCA 1 & 2 Testing Kits
    • 11.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 11.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 11.4.4. Others
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Ovarian Cancer
    • 11.5.2. Breast Cancer
    • 11.5.3. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Pharmaceutical Companies
    • 11.6.3. Diagnostic Laboratories
    • 11.6.4. Academic and Research Institutions
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Myriad Genetics, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Illumina, Inc.
    • 12.3.3. Amoy Diagnostics Co., Ltd.
    • 12.3.4. QIAGEN
    • 12.3.5. Agilent Technologies, Inc.
    • 12.3.6. Quest Diagnostics Incorporated
    • 12.3.7. Foundation Medicine, Inc.
    • 12.3.8. OncoDNA
    • 12.3.9. 4baseCare
    • 12.3.10. AstraZeneca
    • 12.3.11. Laboratory Corporation of America(R) Holdings
    • 12.3.12. Genekor | MEDICAL S.A
    • 12.3.13. Cambridge Bioscience Limited
    • 12.3.14. BPS Bioscience, Inc.
    • 12.3.15. BMG Labtech
    • 12.3.16. R&D Systems, Inc (BioTechne)
    • 12.3.17. BellBrook Labs
    • 12.3.18. Abyntek Biopharma S.L.
    • 12.3.19. Epic Sciences
    • 12.3.20. Reaction Biology

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations